Protalix BioTherapeutics Affirms FY2026 Sales Guidance of $78.000M-$83.000M vs $71.359M Est
Benzinga Newsdesk 7 hours ago
NewsGuidance
Protalix BioTherapeutics (AMEX:PLX) affirms FY2026 sales outlook from $78.000 million-$83.000 million to $78.000 million-$83.000 million vs $71.359 million estimate.
Protalix BioTherapeutics (AMEX:PLX) affirms FY2026 sales outlook from $78.000 million-$83.000 million to $78.000 million-$83.000 million vs $71.359 million estimate.